Which OTC brands pharmacists recommend most — and where the evidence disagrees
Every year pharmacists are surveyed on which over-the-counter brands they recommend, and the same names keep winning. That tells you a product is familiar and safe — not that it works. Two of the biggest winners are a vitamin C drink for immunity and a glucosamine supplement for joints, and the best studies on both came back largely negative. They are unlikely to hurt you. They are also unlikely to do what the box implies.
The annual Pharmacy Times OTC Guide surveys around 1,700 practising pharmacists and names the most-recommended brand in roughly 145 categories. It is a genuine popularity signal and a useful shortlist — but it measures what pharmacists reach for, not what the trials support, and in two of the categories this site covers the two diverge sharply. Emergen-C leads immune support, yet the Cochrane review finds vitamin C does not reduce how often adults catch colds and has no consistent effect when started after symptoms begin, which is exactly how most people take it. Osteo Bi-Flex leads joint health, yet the NIH's GAIT trial found glucosamine and chondroitin no better than placebo for the primary pain endpoint. Neither is unsafe. Both are widely recommended for a benefit the evidence does not clearly deliver.
- The OTC Guide is a survey of pharmacist recommendation, not a review of clinical evidence. Treat it as a shortlist of what is familiar, established and safe — not as a ranking of what works.
- Vitamin C (Emergen-C): regular supplementation did not reduce cold incidence across 29 comparisons in 11,306 people. Duration fell about 8% in adults taking it continuously — and there was no consistent effect when it was started after symptoms appeared.
- Glucosamine + chondroitin (Osteo Bi-Flex): in the NIH-funded GAIT trial, neither supplement nor the combination beat placebo on the primary endpoint of 20% knee-pain reduction over 24 weeks.
- GAIT's one positive signal was an exploratory subgroup with moderate-to-severe pain (79% vs 54% placebo). Exploratory subgroup findings generate hypotheses; they do not establish effect.
- Safety is the part the survey gets right. Adverse events in GAIT were mild, rare, and evenly distributed. The honest verdict on both is low-risk and low-expectation, not dangerous.
CureMed grades this on human trial evidence; animal data never raises a grade.
What the survey actually measures
The OTC Guide, read accurately
| Question | Answer |
|---|---|
| Who is surveyed? | Around 1,700 practising US pharmacists, via Healthcare Research & Analytics |
| How many categories? | Roughly 145, from pain relief and cough/cold to skin care and vitamins |
| What is the output? | The most-recommended brand per category — a popularity ranking among pharmacists |
| What it is good evidence of | Familiarity, tolerability, safety in routine use, and absence of obvious interaction problems |
| What it is NOT evidence of | That the product produces the benefit it is bought for; no trial data enters the ranking |
Immune support: the category where usage and evidence part company
Emergen-C is the standout pharmacist pick for immune support, and it is essentially a high-dose vitamin C drink. The Cochrane review of vitamin C for the common cold is one of the most replicated questions in the whole supplement literature, and its findings are unusually clear.
Regular supplementation did not reduce how often adults caught colds — across 29 trial comparisons in 11,306 participants, incidence was unchanged. Among people taking it continuously as prevention, cold duration fell by about 8% (95% CI 3–12%), a statistically real but small effect. The finding that matters most commercially is the third one: in trials where vitamin C was started after symptoms began, there was no consistent effect on duration or severity at all.
That last scenario is how effervescent vitamin C is overwhelmingly used and marketed — reached for at the first scratch of a sore throat. It is the one use the trials do not support.
Joint health: a negative primary endpoint that never reached the shelf
Osteo Bi-Flex leads the joint-health category, built on glucosamine and chondroitin. That pairing was tested properly, by the NIH, in the Glucosamine/Chondroitin Arthritis Intervention Trial — a 24-week randomised, double-blind, placebo-controlled study that also included celecoxib as an active comparator, published in the New England Journal of Medicine.
On the primary endpoint — the proportion of patients achieving a 20% reduction in knee pain — neither glucosamine alone, chondroitin alone, nor the combination significantly beat placebo. Celecoxib, the active control, did.
GAIT — what was found, and how strong it is
| Finding | Strength |
|---|---|
| Glucosamine, chondroitin, or both vs placebo on 20% knee-pain reduction | Primary endpoint — not significant |
| Celecoxib vs placebo (~70% vs ~60% responders) | Active control — significant, and the trial's internal proof it could detect an effect |
| Combination in the moderate-to-severe pain subgroup (~79% vs ~54%) | Exploratory subgroup — hypothesis-generating only |
| Adverse events | Mild, rare, evenly distributed across groups |
How to use a pharmacist-recommended list properly
- Use it to choose WITHIN a category you have already decided to buy from — it is a good guide to the safest, best-tolerated option on that shelf.
- Do not read it as evidence that the category works. Nothing about trial results enters the ranking.
- Check the specific claim you are buying against the specific way you intend to use it. Vitamin C taken continuously and vitamin C taken at first symptom have different evidence, and only one of them is how most people use it.
- Treat low risk and low benefit as a legitimate combination. Neither product here is dangerous; both are cheap; if you find one useful, the downside is your money rather than your health.
- Bring the interaction question to a pharmacist directly — that is the part of their recommendation the survey captures best, and the part most worth having.
Frequently asked questions
Which OTC brands are recommended most often by pharmacists?
The reference source is the Pharmacy Times OTC Guide, an annual survey of roughly 1,700 practising US pharmacists covering about 145 categories, now in its 30th edition. Recent standouts include Flonase for intranasal corticosteroids, CeraVe for therapeutic skin cleansers, Cortizone-10 for bites and stings, Emergen-C for immune support, Osteo Bi-Flex for joint health and Biotene for dry mouth. It ranks pharmacist recommendation, not clinical evidence — the two are not the same thing.
Does Emergen-C actually work for colds?
Not in the way it is usually taken. The Cochrane review found that regular vitamin C supplementation does not reduce how often adults catch colds, and shortens cold duration by only about 8% in people taking it continuously. When vitamin C was started after symptoms began — the standard use case for an effervescent sachet — no consistent effect on duration or severity was found. It is safe and cheap; it is not doing much.
Is glucosamine and chondroitin worth taking for knee pain?
The NIH-funded GAIT trial tested exactly this over 24 weeks and found neither supplement, alone or combined, significantly better than placebo on its primary endpoint of 20% knee-pain reduction. Celecoxib, included as an active comparator, did beat placebo — so the trial could detect real pain relief. An exploratory subgroup with moderate-to-severe pain did show benefit, but exploratory subgroups generate hypotheses rather than settle them. Adverse events were mild and rare, so the realistic trade is cost against a low probability of benefit.
Should I ignore pharmacist recommendations then?
No — read them for what they are. A pharmacist's pick is strong evidence about safety, tolerability and interaction risk, which is genuinely the part most people get wrong on their own. It is simply not evidence about efficacy, because no trial data feeds the ranking. Use the list to choose the safest option within a category, and use the trial evidence to decide whether the category is worth buying from at all.
Keep reading
- The best longevity supplements, ranked by human evidence
The same standard applied to the longevity shelf — human trials only, animal data never raises a grade.
- Is there a pill that can make you live to 150?
What happens when a mechanism story outruns the trial evidence behind it.
- How we grade evidence
The criteria behind every verdict on this page.
More in Supplements
- The best vitamins for longevity, ranked by human trial evidence
Vitamin D if your level is low, B12 if you are at risk, magnesium for most. Graded only on human randomised trials, including the two that showed harm.
- Best sleep aids, ranked by evidence.
Diphenhydramine stops working in about three nights. Melatonin is modest for insomnia, strong for jet lag. Every OTC sleep aid ranked on its human trials.
- OTC cold and flu remedies, ranked by evidence
The FDA says the decongestant in most cold products does not work. Zinc works only above a dose most lozenges miss. Every OTC cold remedy ranked on its trials.
- PCC1 and the grape-seed longevity pill: what the study actually showed
PCC1 extended mouse lifespan by 9.4% — by injection, starting in old age. Here is the full study, the human data that exists, and what the capsules leave out.
- Taurine and longevity: what the human evidence actually shows
The study that made taurine famous extended lifespan in mice, not humans. What the actual human trials show, the dose studied, and who should be careful.
- Creatine and aging: the best-documented compound in longevity
Creatine has more human trials than any other longevity supplement, at a fraction of the price. What's proven for aging, the dose, and who should be careful.